Suggested remit - To appraise the clinical and cost effectiveness of apalutamide within its marketing authorisation for treating metastatic hormone-sensitive prostate cancer
The company that markets apalutamide has requested a meeting with OMA to determine the feasibility of conducting a molecule rather than indication specific appraisal. NICE will suspend the appraisal until the OMA engagement is complete and the most appropriate route and format to progress with the evidence submission is agreed.
 
Status Suspended
Process STA 2018
ID number 1534

Project Team

Project lead Jeremy Powell

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
25 June 2019 Suspended, The company that markets apalutamide has requested a meeting with OMA to determine the feasibility of conducting a molecule rather than indication specific appraisal. NICE will suspend the appraisal until the OMA engagement is complete and the most appropriate route and format to progress with the evidence submission is agreed.
21 March 2019 - 18 April 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
20 July 2018 In progress, Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance